Deal with global ad agency highlights rising demand for secure generative AI in regulated industries
Brand Engagement Network (BNAI) announced a new commercial milestone as it continues to gain traction in healthcare-focused artificial intelligence. The company revealed it has entered into a Vendor Services Project Agreement with a leading global advertising and communications agency—part of one of the world’s largest advertising holding companies—to develop a custom AI-powered engagement solution for a top 10 global pharmaceutical company.
The project centers on creating a tailored AI communication method to support an established prescription drug, underscoring the growing role of generative AI in patient engagement and pharmaceutical communications. While the identities of the pharmaceutical client and agency remain confidential pending a formal product launch, the agreement reflects increasing confidence in Brand Engagement Network’s secure AI capabilities within highly regulated environments.
Under the terms of the agreement, Brand Engagement Network Inc. expects to recognize approximately $250,000 in revenue for development services tied to two Statements of Work during the fourth quarter of 2025. In addition to this upfront revenue, the company anticipates generating monthly recurring license fees beginning in the first quarter of 2026, creating a longer-term revenue stream beyond the initial build phase.
The deal builds on a series of recent strategic moves by Brand Engagement Network aimed at expanding its healthcare presence. Alongside the new pharmaceutical engagement, the company recently announced an exclusive Latin American licensing partnership and a new venture to launch Skye Salud, an AI-driven healthcare platform focused on the Mexican market. Together, these initiatives are expected to contribute positively to fourth-quarter 2025 results while reinforcing the company’s position in both the U.S. and Latin American healthcare ecosystems.
Acting Chief Executive Officer Tyler Luck said the agreement highlights BEN’s progress in delivering trusted, secure, and efficient AI solutions for pharma manufacturers, healthcare providers, and patients. He emphasized the company’s commitment to building AI-powered experiences that prioritize accuracy, reliability, and integrity—key requirements in healthcare and life sciences.
As pharmaceutical companies and their partners increasingly turn to AI to improve communication, education, and engagement, Brand Engagement Network’s focus on safety and compliance may give it a competitive edge. The latest agreement suggests that adoption of secure generative AI in healthcare is accelerating, positioning BEN for continued growth as demand expands across global markets.
You might like this article:Precious Metals Surge to Record Highs as Safe-Haven Demand Explodes
